Orally Administered SYN-020 Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 2021 ROCKVILLE, Md., June 29, 2021 ...
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual ...
– Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations – – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results